Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Neurizon Therapeutics Limited: Strengths and Weaknesses

Highlights: Neurizon Therapeutics Limited
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Rating Financials

Neurizon Therapeutics Limited SectorAustralia

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Neurizon Therapeutics Limited SectorAustralia

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Neurizon Therapeutics Limited SectorAustralia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Neurizon Therapeutics Limited SectorAustralia

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

Neurizon Therapeutics Limited SectorAustralia

Financial revisions

-

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

-

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.6Cr - - - - - -
91TCr
A
55TCr
BBB
38TCr -
AA
- -
33TCr
AA
29TCr
A
29TCr
AAA
28TCr
A
20TCr
A
18TCr
A
Average 34.09TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. NUZ Stock
  4. Ratings Neurizon Therapeutics Limited